These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23777778)

  • 1. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
    Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
    Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
    Bärfacker L; Kuhl A; Hillisch A; Grosser R; Figueroa-Pérez S; Heckroth H; Nitsche A; Ergüden JK; Gielen-Haertwig H; Schlemmer KH; Mittendorf J; Paulsen H; Platzek J; Kolkhof P
    ChemMedChem; 2012 Aug; 7(8):1385-403. PubMed ID: 22791416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
    Ogawa AK; Bunte EV; Mal R; Lan P; Sun Z; Crespo A; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Jochnowitz N; Ma X; Pan Y; Brown P; Zamlynny B; Bateman T; Leung D; Xu L; Tong X; Liu K; Crook M; Sinclair P
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2866-2869. PubMed ID: 27161805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.
    Lotesta SD; Marcus AP; Zheng Y; Leftheris K; Noto PB; Meng S; Kandpal G; Chen G; Zhou J; McKeever B; Bukhtiyarov Y; Zhao Y; Lala DS; Singh SB; McGeehan GM
    Bioorg Med Chem; 2016 Mar; 24(6):1384-91. PubMed ID: 26897089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
    Casimiro-Garcia A; Piotrowski DW; Ambler C; Arhancet GB; Banker ME; Banks T; Boustany-Kari CM; Cai C; Chen X; Eudy R; Hepworth D; Hulford CA; Jennings SM; Loria PM; Meyers MJ; Petersen DN; Raheja NK; Sammons M; She L; Song K; Vrieze D; Wei L
    J Med Chem; 2014 May; 57(10):4273-88. PubMed ID: 24738581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
    Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
    Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.
    Piotrowski DW; Futatsugi K; Casimiro-Garcia A; Wei L; Sammons MF; Herr M; Jiao W; Lavergne SY; Coffey SB; Wright SW; Song K; Loria PM; Banker ME; Petersen DN; Bauman J
    J Med Chem; 2018 Feb; 61(3):1086-1097. PubMed ID: 29300474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.
    Nordqvist A; O'Mahony G; Fridén-Saxin M; Fredenwall M; Hogner A; Granberg KL; Aagaard A; Bäckström S; Gunnarsson A; Kaminski T; Xue Y; Dellsén A; Hansson E; Hansson P; Ivarsson I; Karlsson U; Bamberg K; Hermansson M; Georgsson J; Lindmark B; Edman K
    ChemMedChem; 2017 Jan; 12(1):50-65. PubMed ID: 27897427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
    Baxter JD; Funder JW; Apriletti JW; Webb P
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):151-65. PubMed ID: 15134814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.
    Hasui T; Ohra T; Ohyabu N; Asano K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
    Bioorg Med Chem; 2013 Oct; 21(19):5983-94. PubMed ID: 23958516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship studies of novel 3-oxazolidinedione-6-naphthyl-2-pyridinones as potent and orally bioavailable EP3 receptor antagonists.
    Morales-Ramos ÁI; Li YH; Hilfiker M; Mecom JS; Eidam P; Shi D; Tseng PS; Brooks C; Zhang D; Wang N; Jaworski JP; Morrow D; Fries H; Edwards R; Jin J
    Bioorg Med Chem Lett; 2011 May; 21(10):2806-11. PubMed ID: 21514150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.
    Roos K; Hogner A; Ogg D; Packer MJ; Hansson E; Granberg KL; Evertsson E; Nordqvist A
    J Comput Aided Mol Des; 2015 Dec; 29(12):1109-22. PubMed ID: 26572910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of sterically encumbered 11β-aminoprogesterone derivatives and evaluation as 11β-hydroxysteroid dehydrogenase inhibitors and mineralocorticoid receptor antagonists.
    Pandya K; Dietrich D; Seibert J; Vederas JC; Odermatt A
    Bioorg Med Chem; 2013 Nov; 21(21):6274-81. PubMed ID: 24074876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
    Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
    FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
    Martín-Martínez M; Pérez-Gordillo FL; Álvarez de la Rosa D; Rodríguez Y; Gerona-Navarro G; González-Muñiz R; Zhou MM
    J Med Chem; 2017 Apr; 60(7):2629-2650. PubMed ID: 28051871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
    Collin M; Niemann F; Jaisser F
    Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
    Piotrowski DW
    J Med Chem; 2012 Sep; 55(18):7957-66. PubMed ID: 22866979
    [No Abstract]   [Full Text] [Related]  

  • 19. Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40).
    Zahanich I; Kondratov I; Naumchyk V; Kheylik Y; Platonov M; Zozulya S; Krasavin M
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3105-11. PubMed ID: 26096679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid Receptor Antagonists.
    Nordqvist A; Granberg KL
    Vitam Horm; 2019; 109():151-188. PubMed ID: 30678854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.